When was Watchmaker Genomics founded?

Watchmaker Genomics was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is Watchmaker Genomics located?

Watchmaker Genomics is headquartered in Boulder, United States.

How many employees does Watchmaker Genomics have?

As of Jun 30, 2026, the latest employee count at Watchmaker Genomics is 265.

Is Watchmaker Genomics a funded company?

Watchmaker Genomics is a funded company, having raised a total of $48.3M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Dec 04, 2020.

When was the latest funding round of Watchmaker Genomics?

Watchmaker Genomics' latest funding was a $***** Series A round on Jun 02, 2022, with participation from 2 investors. Its primary sector is Life Sciences Platforms and Tools. In United States, the Life Sciences Platforms and Tools sector has seen $909M in funding in 2026 to date.

Where does Watchmaker Genomics rank among its competitors?

Watchmaker Genomics ranks 23rd amongst 2080 active competitors, of which 500 are funded. It stands 10th in terms of total funding among its competitors. The most recent competitor to raise funding was Antheia, which secured $24M in Jan, 2026.

Who are the top competitors of Watchmaker Genomics?

Watchmaker Genomics' top competitors include Beam Therapeutics, Antheia and Transcenta. Among them, Antheia secured the most recent funding round in January, 2026.

Watchmaker Genomics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of gene-editing technology. It is developing protein engineering with enzyme manufacturing technology which is used for genomic technology. It offers high-performance enzymes and kits used in next-generation sequencing (NGS) and other molecular biology research applications.

Website: www.watchmakergenomics.com/
Email ID: *****@watchmakergenomics.com

Key Metrics

Founded Year

2018

Location

Boulder, United States

Stage

Series A

Total Funding

$48.3M in 2 rounds

Latest Funding Round

Series A, Jun 02, 2022, $*****

Investors

Eclipse & 1 more

Ranked

23^rd among 2080 active competitors

Employee Count

265 as on Jun 30, 2026

Similar Companies

Beam Therapeutics & 2800 more

View Watchmaker Genomics' full profile

Watchmaker Genomics has raised a total funding of $48.3M over 2 rounds. Its first funding round was on Dec 04, 2020. Its latest funding round was a Series A round on Jun 02, 2022 for $*****. 2 investors participated in its latest round. Watchmaker Genomics has 2 institutional investors.

Here is the list of recent funding rounds of Watchmaker Genomics:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 02, 2022	6675852	Series A	1161984	5648709	7176650	3905500
Dec 04, 2020	5495815	Seed	3254982	3773977	6572752	4310283

Access funding benchmarks and valuations. Sign up today!

View details of Watchmaker Genomics's funding rounds and investors

The founders of Watchmaker Genomics are Brian Kudlow and Stephen Picone.

Here are the details of Watchmaker Genomics' key team members:

Brian Kudlow: Co-Founder of Watchmaker Genomics.
Contact Info: 1 email address
Stephen Picone: Co-Founder & CSO of Watchmaker Genomics.
Contact Info: 1 email address

View details of Watchmaker Genomics's Founder profiles and Board Members

Watchmaker Genomics' employee count trend

Watchmaker Genomics has 265 employees as of Jun 26. Here is Watchmaker Genomics's employee count trend over the years:

Employee count trend for Watchmaker Genomics

Uncover Watchmaker Genomics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Watchmaker Genomics include Beam Therapeutics, Antheia and Transcenta. Here is the list of Top 10 competitors of Watchmaker Genomics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Beam Therapeutics 2017, Cambridge (United States), Public	Developer of gene therapy using CRISPR base editing to treat diseases	$222M	F-Prime Capital, Cormorant-asset & 16 others	71/100
2nd	Antheia 2013, Palo Alto (United States), Series C	Genetically engineered yeast cells to produce medicinal products	$176M	Viking Global Investors, ATHOS KG & 15 others	67/100
3rd	Transcenta 2019, Suzhou (China), Public	Developer of antibody-based therapeutics	$205M	Lilly Asia Ventures, Temasek & 11 others	66/100
4th	eGenesis 2015, Cambridge (United States), Series D	Developer of a gene transplantation platform for humanizing pig cells	$481M	Samsara BioCapital, Monashee Investment Management ... & 30 others	65/100
5th	Mammoth 2017, Brisbane (United States), Series D	Provider of molecular diagnostics platform by using CRISPR technology	$271M	Redmile Group, NFX & 34 others	65/100
6th	Akeso 2012, Zhongshan (China), Public	Developer of antibody drug conjugates for the treatment of broad spectrum diseases	$195M	Orbimed, Sino Biopharmaceutical & 18 others	65/100
7th	Metagenomi 2016, Berkeley (United States), Public	Digital gene editing technologies for drug development	$376M	Humboldt Fund, SymBiosis & 22 others	64/100
8th	Locus Biosciences 2015, Raleigh (United States), Series B	Developer of therapeutics for infectious disease and inflammatory indications	$67.3M	Artis Ventures, Illumina & 13 others	64/100
9th	Korro Bio 2018, Cambridge (United States), Public	Provider of RNA editing technologies to develop genetic medicines for rare and prevalent diseases	$4M	Cormorant Asset Management, New Enterprise Associates ... & 14 others	64/100
10th	Prime Medicine 2019, Cambridge (United States), Public	Developer of genetic therapies for a wide range of diseases	$315M	T. Rowe Price, F-Prime Capital & 10 others	64/100
23rd	Watchmaker Genomics 2018, Boulder (United States), Series A	Developer of gene-editing technology	$48.3M	Eclipse, Decheng Capital	60/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Watchmaker Genomics's competitors? Click here to see the top ones

Watchmaker Genomics has made no investments or acquisitions yet.

Here is the latest report on Watchmaker Genomics's sector:

Free

Consumer - Sector Report

Edition: July, 2026 (133 Pages)

View all reports related to Watchmaker Genomics

Media has covered Watchmaker Genomics for a total of 14 events in the last 1 year, 6 of them have been about company updates and 6 about partnerships.